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Abstract 
Aim 
We conducted a systematic review of the use of continuous glucose monitoring (CGM) in 
older patients, in order to consolidate the growing evidence base in this area. 
 
Methods 
Our protocol was registered on PROSPERO (CRD42017068523). 
 
We searched SCI Web of Science, Ovid SP MEDLINE and EMBASE from January 2010 to June 
2017 for observational studies and randomized controlled trial of CGM in older patients 
(mean age 65 or older) with diabetes.  We excluded studies that involved only hospitalized 
patients.  Two reviewers independently extracted data blood sugar values (in particular, 
hypoglycemic episodes) captured with the use of CGM. We also assessed adverse events 
and acceptability of CGM. 
 
Results 
After screening 901 abstracts, we included nine studies with a total of 989 older patients 
with diabetes.   
The CGM studies reveal that hypoglycemic episodes were occurring in a sizeable proportion 
(28-65%) of participants. Most (80-100%) of these episodes were asymptomatic, with some 
patients spending nearly two hours per day in the hypoglycemic range.  Older people with 
diabetes found CGM acceptable and experienced improved health-related well-being. 
 
Conclusion 
CGM frequently picks up asymptomatic hypoglycemic episodes in older patients with 
diabetes. Users of CGM report improved well-being, and reduction of diabetes-related 
stress. 
 
Keywords: hypoglycemia; older people; continuous glucose monitoring  
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1 Introduction 
Self-management of diabetes mellitus in older people with multiple comorbidities (including 
cognitive impairment) is challenging, because the extent of harm from hypoglycemia, and 
the optimal means of monitoring blood glucose in this population, is not known. Current 
strategies of monitoring (such as glycated hemoglobin or intermittent finger-prick testing) 
may not be entirely appropriate for older patients who face difficulties in recognizing and 
managing changes in blood sugars 
 
Recent research has demonstrated that routine self-monitoring of blood glucose (SMBG) in 
patients with non-insulin treated type 2 diabetes mellitus does not significantly improve 
Hemoglobin A1C (HbA1c) level or health-related quality of life (1) (2).   Young et al 
conducted a pragmatic open-label randomized trial of 450 patients in 15 primary care 
practices in North Carolina.  Three SMBG approaches were compared: no SMBG, once-daily 
SMBG and once-daily SMBG with enhanced patient feedback.  No clinically or statistically 
differences at one year in glycemic control or health-related quality of life were observed 
between those who did or did not perform S BG (1). 
 
Malanda et al. conducted a Cochrane Review in 2012 that assessed the effects of 12 
randomized controlled trials of SMBG in patients with type 2 diabetes who were non-insulin 
users.  The reviewers concluded that when diabetes duration is over one year, the overall 
effect of SMBG on glycemic control is small up to six months after initiation and subsides 
after 12 months.  The reviewers could not find evidence that SMBG affects health-related 
quality of life or patient satisfaction (2). 
 
However, existing research has focused on markers of long-term efficacy or benefit, 
whereas for older people, the threat of hypoglycemia may be a far more immediate and 
pressing concern. Recent evidence from Asia shows a sharp rise in emergency admission for 
hypoglycemia – for instance, over a ten-year period, older people in Korea were found to 
have a 10-fold increased risk of hypoglycemic episodes needing hospital admission (3) (4). A 
study in England found that one Ambulance Trust had 523 call outs for severe hypoglycemia 
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(mainly in older people) over a 3-month period, with projected costs exceeding £235,000 
per year (5).  
 
Recent advances in continuous glucose monitoring (CGM) technology may uncover the true 
extent of (otherwise undetected) hypoglycemia. An observational study by Pazos et al in 
2015 enrolled patients with type 2 diabetes who were > 60 years of age, and concluded that 
CGM was useful because it succeeded in detecting an almost five-fold higher rate of 
hypoglycemic events than through SMBG.(6).  It is becoming clear that new approaches or 
changes in mindset are needed when formulating monitoring strategies for older patients, 
aimed towards measuring harm from hypoglycemia rather than efficacy targets. Hence, we 
have undertaken a systematic review on the role of CGM in older people, with specific focus 
on ascertainment of asymptomatic hypoglycemia. 
   
2 Methods   
Our protocol was registered on PROSPERO (CRD42017068523). 
 
2.1 Study selection criteria 
We included observational studies and randomized controlled trials (RCT).  Population of 
interest was older people, mean age >65 years.  Studies based solely on inpatients or 
laboratory settings were excluded. 
 
2.2 Search Strategy 
We searched three electronic databases -  Web of Science, Ovid SP MEDLINE and EMBASE 
from January 2010 to June 2017. 
 
No searches were conducted on unpublished or grey literature. Only human studies were 
included in the search. 
 
The search strategy included terms related to the intervention (continuous glucose 
monitoring) and the population (older adults): 
 
(Aged OR "older adult" OR "older adults" OR elderly OR geriatric OR veteran? OR senior?) 
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AND  
 
(continuous-glucose-monitoring or CGM) 
 
We also conducted a manual search by reviewing the reference lists of included studies and 
published systematic reviews on the same topic. The searches were also updated 
automatically on a monthly basis through electronic notifications from Pubmed. 
 
2.3 Study Selection and Data Extraction 
Two reviewers (YKL and KM) independently screened titles and abstracts to remove those 
that clearly did not fulfil selection criteria. Both reviewers then proceeded to check full-text 
versions of articles that were either of uncertain suitability or were judged as potentially 
relevant.  Data extraction similarly involved two independent reviewers, with subsequent 
discussion to reach consensus. 
 
We extracted the following information onto a spreadsheet: study design, geographical 
location, sample size, mean age, diabetes duration, model/make of CGM, selection of 
patients, loss to follow-up, missing data, selective reporting, summary statistics of blood 
sugar values captured, definition and number of hypoglycemic episodes captured, adverse 
events, acceptability and adherence (please refer to Appendix B Tables B.1 and B.2). 
 
2.4 Quality assessment 
Two reviewers assessed key parameters, including selection of patients, loss to follow-up, 
missing data, selective reporting and analysis. 
 
2.5 Data synthesis/Analysis  
We aimed to perform meta-analysis if there was sufficient quantitative data and similarity in 
the reported outcome measures. Assessment of statistical heterogeneity would be through 
the I2 statistic.  We aimed to assess publication bias by examining funnel plots, if there were 
more than 10 included studies for a particular outcome, and there was no evidence of 
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significant heterogeneity.   Where studies were too heterogeneous to be pooled, a narrative 
analysis of the data would be undertaken. 
 
 
3 Results 
After de-duplication, we screened 901 citations and one citation from automated 
notification.  We included nine studies. (see Appendix A Figure A.1 PRISMA flow chart) (7) 
(8, 9) (10-13) (14) (15). 
 
The included studies had a total of 989 participants (sample size 22 to 285) with a mean age 
of 70 years.  Geographical locations were diverse and included North America, Japan, 
Canada, Germany and the Netherlands. 
 
3.1 Risk of Bias of Included Studies and Selective Outcome Reporting 
There was a mix of types of studies, including RCT, retrospective health record reviews, 
cross-sectional studies, pilot study and mixed-method study.   
Most of the studies did not provide sufficient information on blinding of assessors and 
participants, drop-out rates, missing data and how missing data were addressed.  Only three 
studies employed blinding of the device readings (15) (9) (13).  In addition, there is 
considerable variation in the definition of hypoglycemia amongst the included studies. 
 
3.2 Evidence Synthesis 
The nine included studies did not have sufficient quantitative data and similarity in the 
reported outcome measures for us to pool the data in a meta-analysis. 
 
We have therefore carried out a narrative synthesis under the following headings: 
 Capture of hypoglycemia 
 CGM satisfaction 
 Association of adverse events with hypoglycemia 
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 Pre-and post CGM outcomes 
 
 
Capture of hypoglycemia 
Four studies report on the number of participants who had hypoglycemic episodes recorded 
through blinded CGM (14) (9) (10) (13).   
Figure 1(a) depicts the number of patients with and without hypoglycemia. 
 
The proportion of participants affected by at least one or more hypoglycemic event varied 
between 28%-65%.   This variation may have stemmed from differences in patient 
characteristics, nature of drug therapy and duration of monitoring (ranged from 3 to 5 
days), nevertheless, the important unifying features of all of these studies is that CGM has 
demonstrated that a substantial proportion of older people are affected by hypoglycemic 
events. 
 
We extracted data from three studies regarding the symptomatic or asymptomatic nature 
of the hypoglycemic episodes (9, 10)  (13). Figure 1(b) illustrates number of hypoglycemic 
events with and without symptoms.   All three studies used blinded CGM. 
 
 It is striking that between 80-100% of hypoglycemic events were asymptomatic  
and arguably most if not all of these would have gone unnoticed had it not been for the use 
of CGM at that particular point in time. 
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Figure 1(a) Number of patients with and without hypoglycemia (blinded CGM) 
 
 
Figure 1(b) Number of hypoglycemic events, with and without symptoms 
 
 
Finally, we estimated the length of time participants spent in the hypoglycemic range in 
minutes per day (see Figure 2)  (15) (12, 13) (9) (10).   
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Participants in the observational studies spent between 34-112 minutes per day in the 
hypoglycemic range, whereas the baseline blinded CGM in the randomized trial by Ruedy et 
al. found that participants spent only between 8-10 minutes in the hypoglycemic range. 
 
There are a number of reasons why the RCT data are outliers.  The investigators conducted 
a post-hoc analysis of older participants in the multi-centre DIAMOND RCT comparing CGM 
versus self-monitoring (16).  Participants all had to have a stable diabetes regime for three 
months prior to study entry, and were performing self-monitoring three or more times 
daily, with no history of recurrent hypoglycemia (16).  Co-morbidities such as recent 
cardiovascular disease, significant heart failure, conditions resulting in physical or cognitive 
decline, and renal impairment were listed as exclusion criteria.  The participants selected for 
the DIAMOND trial were not frail older people with multiple co-morbidities and possible 
cognitive impairment. Instead, the participants were likely to have good hypoglycemic 
awareness and ability to correct low blood sugars more quickly than those the frail older 
participants in van Dijk’s study where all of the hypoglycemic episodes were asymptomatic 
(13).   
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Figure 2 Minutes per day in the hypoglycemic range (blinded CGM) 
 
 
 
CGM satisfaction 
CGM satisfaction was assessed in two studies where users were not blinded to the functions 
of the device  (8) (12).  Litchman et al’s mixed-methods study, used convenience sample of 
older adults with type 1 diabetes who completed one of two online surveys about CGM.  
Emerging themes were that CGM use facilitates feelings of safety by preventing 
hypoglycemia and improves well-being.  CGM users felt that they were able to function 
better in their daily activities and that the device could assist in prolonging life by preventing 
injury and complication  (8).  
 
In Ruedy et a’s study, CGM users (n=60) were asked to complete a CGM Satisfaction Survey 
at the 24-week follow-up.  Overall satisfaction was high with mean score of 4.2 (range of 
scores 1-5), with mean scores of 4.3 on the Benefits subscale and 1.8 on the Hassles 
subscale, indicating that the perceived benefits outweighed the perceived hassles (12). 
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Adverse events 
Three studies reported on adverse events, such as Emergency Department (ED) visits (11), 
falls, inability to operate a vehicle in the last year (8) and ventricular arrhythmias (10).  It is 
important to note that at this juncture, we cannot draw any conclusions regarding causality 
between the hypoglycemic episodes and adverse events. 
 
Litchman et al asked participants to complete an online survey which included a question on 
whether hospitalization had occurred in relation to a participant’s diabetes since they had 
started using CGM, which was compared to hospitalization on non-CGM users.  The results 
of that particular question are not reported.  However, CGM users (n=11) reported 0 severe 
hypoglycemic episodes resulting in a fall or inability to operate a vehicle in the last year, 
compared to 6 non-CGM users (55%) (8). 
 
Pistrosch et al looked at the occurrence of ventricular arrhythmias in type 2 diabetes 
patients who had hypoglycemic events. In their study, they observed that 13 out of 26 
patients in the hypoglycemic group experienced ventricular arrhythmias, compared to 11 
out of 68 participants in the non-hypoglycemic group (10). 
 
Adverse events pre- and post-CGM 
Polonsky et al reported reduction of 5.3% of hospitalization in CGM users comparing 
hospitalization six months before starting CGM and over the past six months.  This reduction 
of hospitalization was a within-group comparison (11) .  There was no reduction in 
hospitalization in the non-CGM users in the same period.  In addition, there was a 4.3% 
reduction in car accidents and 12.8% reduction in ED visits for CGM users within that time.  
This compares to a 4% increase in ED visits, 2.6% reduction in car accidents and 0% 
difference in hospitalization for non-CGM users within that same time period. The authors 
report unadjusted and adjusted odds ratios (and some p-values), but no confidence 
intervals, so it is not possible to properly comment on the statistical significance of the 
results. 
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Argento et al’s study was a retrospective electronic health record review where the 
investigators looked at medically recorded hypoglycemia (requiring assistance from a third 
party).  Here, CGM users were shown to have a reduction in severe hypoglycemic episodes 
from 52 (recorded in the five years before CGM initiation) to 12 after starting CGM.  Overall, 
the proportion of patients with any severe hypoglycemia fell from 79% to 31% after 
initiation of CGM (7).  However, we are conscious of the major limitations of these studies 
which are non-randomized, unblinded, and without any specific treatment protocols 
involving glucose-lowering drugs. 
 
4 Discussion 
In this systematic review of CGM, we have evaluated 9 studies with a total of 989 
participants who had type 1 or type 2 diabetes.   There was a diverse range of study designs, 
ranging from pilot studies, mixed method studies, database observational studies and one 
RCT.   
 
Despite the variation in study populations and geographical locations, we found consistent 
evidence that CGM was able to detect hypoglycemic episodes in a sizeable proportion of 
older patients, many of which were asymptomatic. In particular, van Dijk et al’s reported 
that 100% of the CGM recorded hypoglycemic episodes were asymptomatic, with some 
patients having nearly two hours per day in hypoglycemic range (13).   Munshi et al also 
highlighted that 95% of the captured hypoglycemic episodes went unrecognized (9).    
Clinicians and patients would probably have been completely unaware of these prolonged 
asymptomatic episodes in the pre-CGM era, and this may represent a major unrecognized 
health burden in older people with diabetes. 
 
Linked to the asymptomatic hypoglycemic episodes, one could hypothesize that older 
patients (who may have cognitive problems and poor hypoglycemic awareness) are 
spending longer in the hypoglycemic range compared to patients with good hypoglycemic 
awareness, who are able to correct their blood sugar levels in a short amount of time.  
Whilst this appears to be a plausible theory, we are not able to substantiate this with 
evidence, as the included studies do not provide enough information on hypoglycemia 
awareness.  Nevertheless, an important area for further research is whether an increased 
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risk of serious harm is associated with duration of time in hypoglycemic range rather than 
discrete episodes of hypoglycemic events. 
 
In addition to picking up hypoglycemic events, the included studies have highlighted that 
older people with diabetes find the use of CGM acceptable (12) and that it improved well-
being (8).  Litchman et al also reported barriers regarding lack of accessibility, affordability 
and lack of insurance cover which can prevent older people from being able to make use of 
CGM technology (8).  Although many of the studies do not directly draw a link between 
hypoglycemia and subsequent serious events that affect quality of life, we have found three 
studies that venture the possibility of an association with emergency department visits and 
ventricular arrhythmias (8) (10, 11).  
 
Moreover, other meta-analyses have demonstrated significant associations between 
hypoglycemia and subsequent serious complications.   One meta-analysis revealed that 
patients with impaired cognition had significantly greater likelihood of hypoglycemia 
(pooled odds ratio (OR) 1.61 (95% Confidence Interval (CI) 1.25, 2.06)) compared to those 
without.  In turn, those affected by hypoglycemia were more susceptible to worsening 
cognitive impairment and dementia (OR 1.68; 95% CI 1.45, 1.95) (17).   A further systematic 
review in older patients found a significant association between hypoglycemia and falls (OR 
1.89; 95% CI 1.54, 2.32), or fractures (OR 1.92 95% CI 1.56, 2.38), and a near doubling of 
cardiovascular complications and death (18). 
 
In addition to picking up hypoglycemic events, the included studies have highlighted that 
older people with diabetes find the use of CGM acceptable (12) and that it improved well-
being (8).  Litchman et al also reported barriers regarding lack of accessibility, affordability 
and lack of insurance cover which can prevent older people from being able to make use of 
CGM technology (8) .  The advent of flash glucose monitoring may be a more cost-effective 
way to optimize diabetes management. 
 
We recognize important limitations of our systematic review.  The data provided by the 
included studies was too heterogenous to provide an appropriate meta-analysis.  We have 
therefore not been able to provide a quantitative analysis of the data.  The included studies 
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range to mixed-method online surveys to RCTs, which makes it difficult to provide a robust 
analysis of the quality of the data and we only included English-language articles.  Some of 
the studies had a very select group of participants (Caucasian, highly educated and users of 
technological devices) and small sample sizes (<50).  This limits the generalizability to the 
general older population with diabetes.   
 
Rather than using CGM all-year round, we believe it would be more cost-effective to use 
CGM to ‘troubleshoot’ (for example, two weeks every six months) and identify patterns in 
glucose variability (especially asymptomatic hypoglycemia) in older patients.  Intermittent 
finger-prick testing is not useful in this group, because the vast majority of hypoglycemic 
episodes seem to be asymptomatic, and the older patient or carer may not be alerted to the 
need to do the finger-prick test at that point in time.  In addition, the duration of time spent 
in the hypoglycemic range could not be reliably assessed through intermittent finger-prick 
testing.    
 
Further studies should explore possible associations between CGM recorded hypoglycemic 
episodes, duration of time in hypoglycemic range and cognitive and cardiovascular 
outcomes.  This could involve large cohorts of older people with diabetes (especially type 2 
diabetes), with the aim of correlating asymptomatic hypoglycemic episodes with 
subsequent serious adverse outcomes (for example patients could be asked to wear a 14-
day ECG recorder, in order to capture possible arrhythmias occurring at the time of 
hypoglycaemic episodes). In addition, trials of new glucose lowering therapies in older 
patients with diabetes should include the routine use of CGM, so that harmful effects are 
not missed. At present, the inconsistent definition and capture of hypoglycemic episodes 
can lead to a misleadingly rosy picture of glucose lowering therapy in older people because 
the true extent of harm is difficult to analyze whilst the potential beneficial effects may be 
over-emphasized (19). 
 
We believe that the monitoring strategy in older patients should focus on preventing 
imminent or acute harm, rather than long-term complications related to HbA1C which may 
only manifest in 10-20 years’ time which may be beyond the lifespan of some patients. 
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5 Conclusions 
CGM is an innovative technology that can detect otherwise unrecognized hypoglycemic 
events in older patients.  CGM can provide more robust evidence to inform the careful 
balance of avoiding harm from hypoglycemia and long-term diabetes control in such 
patients. 
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Appendix A Figure A.1 PRISMA diagram of study selection 
 
 
PRISMA 2009 Flow Diagram 
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Appendix B Table B.1: Study design and characteristics  
Study ID Study design, setting, 
country 
Patient Characteristics (numbers in 
each group, mean age overall, % male, 
type of diabetes, any 
inclusion/exclusion criteria, 
confounders adjusted for)  
Intervention (which 
model/make of 
CGM), blinded or not 
Argento 
2014 (7) 
Retrospective electronic 
health record review US 
adult endocrinology clinic. 
Any patient >65 years with 
CGM 15 June 2013 
CGM (n=29) 
Age:68.8 (SD 3.5) years 
Male 12/29 (41%) 
T1DM 26/29 (90%) 
All patients used insulin 
Device not stated 
No blinding 
DuBose 
2016 (15) 
T1D Exchange Clinic 
Network in US. 
Non-CGM users, T1DM >60 years age, 
diabetes duration >20years. Exclusions: 
chronic kidney disease stage 4 or 5, 
moderate or advanced dementia, or 
pancreatic 
transplant. 
N=199 
Mean age 68 
Male 53% 
Mean duration of diabetes 40 years 
Blinded participants 
using Dexcom SEVEN 
device, sampling 
glucose every 5 
minutes for a week. 
Device replaced after 
that for further 7 
days. 
Ishikawa 
2017 (14) 
Retrospective 
observational study 
previously collected CGM 
data, Chiba University 
Hospital and Kashiwado 
Hospital Japan 2011-2016. 
N=170 (83% outpatients) type II DM 
age>65 years. 
Mean Age 74.1±6.7 
42.4% on DPP-4 inhibitors, 55.9% on 
with insulin) and 27.1% on SU. 
 
Medtronic iPro v2 or 
System Gold 
Blinded 
Litchman 
2017 (8) 
Two online surveys of CGM 
through Diabetes Online 
Community on Facebook. 
Convenience sample using 
snowball sampling 
technique 
N=11 users 
T1DM >65 years, able to read/write 
English. 
Mean age 69.6 ± 4 years 
Male: 55% 
Diabetes duration 59.4 ± 6.4 y 
Control group N=11 who want to use 
CGM 
Dexcom Gen4 =8 
Dexcom Gen 5 =1 
Medtronic Revel=1 
Medtronic Enlite =1 
 
No blinding 
Munshi 
2011 (9) 
Prospective observational 
study, Tertiary care 
diabetes clinic, USA. 
N=40 
Community-living patients aged ≥69 
years with HbA1C>8% 
 
Blinded Medtronic 
iPro sampling every 5 
minutes for a 3-day 
period 
Pistrosch 
2015 (10) 
Cross-sectional study of 
tertiary centre, Germany 
N=94 
Frail patients with type 2 diabetes with 
a proven cardiovascular event 
Mean age 68 years 
Males: 
Duration of diabetes: 
Medtronic iPro2 
sampling every 5 
minutes for a 5-day 
period 
 
Blinded 
Polonsky 
2016 (11) 
Dexcom, Inc central 
database – email invites 
for participation in online 
survey in US 
N=210 
≥ 65 years of age with Medicare as 
primary insurance or no health 
insurance coverage. 
Mean age 70.4 years 
M: 52.9% 
Presumably Dexcom 
users 
 
Unblinded 
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Duration of diabetes 35.7 years 
T1DM: 93.8% 
T2DM: 6.2% 
Ruedy 
2017 (12) 
Multicentre RCT in US and 
Canada 
N=63 on CGM, N =53 controls 
>60 years, receiving multiple daily 
insulin > 1 year, stable diabetes, 
compliant with Self-monitoring. 
Excluded if recent use of CGM. 
Mean age 67 years 
Duration of diabetes 21 years 
T1DM: 20 (32%) 
T2DM: 43 (68%) 
Dexcom G4 Platinum 
 
All participants had  2 
weeks blinded CGM 
prior to allocation to 
intervention or 
control arms. 
Following that, 
intervention arm 
received unblinded 
CGM with algorithm 
for glucose control. 
Van Dijk 
2017 (13) 
Primary care, Netherlands N=23 
Age ≥ 70 years, T2DM, HbA1c < 58 
mmol/mol (7.5%), and a Groningen 
Frailty Indicator (GFI) score ≥ 4. 
Mean age 76 years 
Male 47% 
Median duration of diabetes 9 years 
Blinded Medtronic 
IPro2 
 
CGM= continuous glucose monitor, DM=Diabetes Mellitus, PCGM= personal real-time continuous glucose monitoring, RT-CGM=real-
time continuous glucose monitoring, CKD=chronic kidney disease, T1DM=Type 1 Diabetes Mellitus, T2DM=Type 2 Diabetes Mellitus, 
SMBG=self-monitoring blood glucose, RCT= Randomised Controlled Trial, SH=severe hypoglycaemia, HE=hypoglycemic event, 
DKA=diabetic ketoacidosis, CVD=cardiovascular disease, AV block=atrioventricular block, PPM=permanent pacemaker, iG=interstitial 
glucose, QOL=quality of life, GFI=Groeningen Frailty indicator, OR= Odds Ratio, 95%CI= 95% Confidence Interval, SU= sulfonylurea, 
DPP4 inhibitor=dipeptidyl peptidase-4 inhibitor, HbA1c=haemoglobin A1c, VT=ventricular tachycaria 
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Appendix B Table B.2: Outcomes 
Study 
ID 
Summary statistics of 
blood sugar values 
captured (mean, 
median, range, 
standard deviation) 
Recording time 
Definition and 
number of 
hypoglycemic 
episodes 
captured  
What 
types 
of 
advers
e 
events 
of 
interes
t were 
specifi
ed or 
define
d? 
 
How 
and 
when 
were 
adverse 
events 
ascertai
ned? 
 
How 
complete was 
follow-up and 
reporting of 
adverse 
events? 
(duration, 
numbers for 
loss to follow-
up, or 
selected 
sample only) 
Was patient 
adherence and 
device 
acceptability 
ascertained? 
Argent
o 
2014 
(7) 
CGM duration 36.8 
(range 4-68) months 
Pre- vs. post-CGM 
outcomes: 
Percent with hypo pre: 
79%  vs..31% (P = 
.0002, n = 29).  No. of 
hypos: pre-  52 
episodes in 5 years 
prior vs. 12 episodes 
after initiating PCGM.  
(5 SH episodes 
occurred while patients 
not using PCGM).  
Yearly rate of SH 0.37 ± 
0.38 vs. 0.12 ± 0.19 (P = 
.0007) 
Severe if patient 
required third-
party assistance 
and counted as 
present 
if there was at 
least 1 recorded 
episode. 
Individual reports 
of SH were 
counted as single 
episodes, and if 
plural or many 
episodes, then 
classified as 
several 
Not 
stated 
Not 
stated 
38 prescribed 
PCGM; 29 
were still 
regularly using 
PCGM, 2 were 
using 
professional 
CGM 
intermittently, 
and 7  
never started 
PCGM (3 
patients) or 
discontinued  
 
Intermittent 
users 
excluded 
Not stated. 
DuBos
e 2016 
(15) 
Median 286 hours out 
of potential maximum 
of 336 hours CGM in 
two weeks. 
CGM recorded 
hypos; 
Minutes per 24 
hrs (% time) 
<3.9 mmol: 91 
(6.3%) 
<3.3 mmol: 55 
(3.8%) 
<2.8 mmol: 31 
(2.2%) 
 
% days with at 
least one hypo 
event 38% 
Not 
stated 
Not 
stated 
Missing data 
varied from 3 
– 15 
participants 
according to 
category of> 6 
hours missing 
data per time 
period (24 h, 
day only, night 
only)  
 
199/201 
patients 
followed-up 
Not stated 
Ishika
wa 
2017 
(14) 
Glucose recordings: 
< 3.9 mmol: 72/170 
% of time in hypo: 2.3% 
< 3.9 mmol, no 
mention of clinical 
event 
Not 
stated 
Not 
stated 
Not stated Not stated 
Litchm
an 
2017 
(8) 
10/11 users said they 
had it on all the time. 
Hypoglycemia 
glucose < 3.9 
mmol;, 
severe 
Hospit
alizatio
n 
Online 
survey 
Selected 
sample – self-
identified as 
high 
Yes. why 
participants 
were 
using/wanted 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 22 
hypoglycemia 
hypoglycemia 
episode 
requiring 
assistance form 
another person,  
hypoglycemia 
unawareness is 
defined as 
occurring when an 
individual with 
diabetes is 
experiencing 
hypoglycemia, but 
feels no 
symptoms. 
technology 
users 
to use RT-
CGM, and how 
RT-CGM was 
affecting/migh
t affect 
diabetes 
management 
and safety 
Muns
hi 
2011 
(9) 
65% of patients 
with A1C >8% were 
found to have ≥1 
hypoglycemic episode 
over a 3-day period. 
 
4 times a day finger-
stick glucose checks did 
not coincide with CGM-
detected hypoglycemia  
 
 
Symptoms – self-
report. 
Analysis of CGM 
according to time, 
duration and 
magnitude of low 
glucose  
 
65% (26/40 
patients) ≥1 
hypoglycemia 
(median glucose 
63 (42–69) 
mg/dl). 
12 (46%) had 
glucose levels <50 
mg/dl, and 19 
(73%) <60 mg/dl. 
Average number 
of episodes 
4 with average 
duration of 46 
minutes. Of a 
total of 102 
hypoglycemic 
episodes, 95 
(93%) were 
unrecognized, 
either by finger-
stick monitoring 
or by symptoms.  
18/ 26 (69%)had 
≥1 nocturnal 
episode (average 
duration 56 
minutes). 
Not 
stated 
Not 
stated 
Not stated Not stated 
Pistros
ch 
2015 
(10) 
Patients perceived only 
39 % of HE during the 
day and 
11 % of HE during the 
night. Patients with HE 
<3.1mmol 
26/94 patients 
had hypo. 
Fifty-four 
episodes of 
Cardio
vascul
ar 
events 
(VT)  
24-hour 
ECG 
monitor
ing 
Not stated Not stated 
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had significantly 
higher number of 
severe ventricular 
arrhythmias 
[ventricular tachycardia 
(VT) 32.8 ± 60 vs. 0.9 ± 
4.2, 
p = 0.019], and 
multivariate regression 
analysis revealed 
the duration of severe 
HE and TSH level as 
independent 
predictors of the 
occurrence of a VT 
hypoglycemia 
(average of 2.4 
episodes per 
patient), with 171 
minutes mean 
duration over 5 
days. Eighteen 
events during 
daytime and 36 
nocturnal 
<3.9 mmol 
4.2 episodes per 
patient with 415 
minutes mean 
duration over 5 
days. 
 
Patients asked to 
record all 
symptoms of 
hypoglycemia 
with date and 
time in diary 
 
Polons
ky 
2016 
(11) 
154 (73.3%) in 6 
months prior to CGM 
as compared to 
recent 6 months with 
CGM 121 (57.6%). 
Drops in the incidence 
of events requiring the 
assistance of another, 
hypoglycemia-related 
hospitalizations, 
ER visits, paramedic 
visits to the home, and 
auto 
accidents 
Hypoglycemia  
frequency of 
low blood 
glucoses (<70 
mg/dl) in the past 
month, 
with and without 
symptoms; over 
the past 6 
months, 
the frequency of 
moderate 
hypoglycemic 
episodes 
(symptoms of 
confusion, 
disorientation, 
lethargy or 
being unable to 
treat oneself) and 
the number of a 
variety of events 
associated with 
severe 
hypoglycemia, 
including episodes 
requiring 
assistance.  
Comparison of 
frequency/numbe
r of 
events during the 
“retrospective 
Health
care 
use 
includi
ng 
param
edic 
visit, 
emerg
ency 
depart
ment 
care, 
road 
accide
nts.  
Online 
survey 
Online survey 
conducted on 
behalf of 
Dexcom (CGM 
manufacturer) 
Not stated 
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baseline period,” 
defined as the 6-
month period 
before they 
first started RT-
CGM vs. current 
period. 
Ruedy 
2017 
(12) 
Mean CGM use was 6.9 
± 0.2 days/week in 
month one; and 6.8 ± 
1.1 in month 6. 
 
HbA1c reduction from 
baseline to 24 weeks 
was greater in the CGM 
group than Control 
group (−0.9 ± 0.7% 
versus −0.5 ± 0.7%, 
adjusted difference in 
mean change −0.4 ± 
0.1%, P < .001). 
Severe 
hypoglycemia (SH) 
event that 
required 
assistance from 
another person to 
administer 
carbohydrates or 
other 
resuscitative 
action 
No serious hypos 
recorded during 
study. 
CGM recorded 
hypos at baseline: 
Median minutes 
per 24 hrs (% 
time) at <3.3 
mmol was 10 
(0.7%) for 
intervention arm 
and 8 (0.6%) for 
control arm. 
 
Not 
stated 
Not 
stated 
Post-hoc 
analysis of 
multicentre 
RCT 
Satisfaction 
with use of 
CGM mean 
score of 4.2 ± 
0.4 on the 
CGM 
Satisfaction 
Survey 
(possible score 
range 1 to 5), 
with mean 
scores of 4.3 ± 
0.5 on the 
Benefits 
subscale and 
1.8 ± 0.5 on 
the Hassles 
subscale 
 
Van 
Dijk 
2017 
(13) 
Monitoring period – 97 
hours median (out of 
maximum of 120 
hours) 
Hypo < 3.0mmol: 
5 patients had 15 
events (245 
minutes total) 
Hypo <3.5 mmol: 
8 patients had 25 
events (292 
minutes total). 
None of the 
patients reported 
symptoms. 
Not 
stated 
Not 
stated 
Not stated Not stated 
 
CGM= continuous glucose monitor, DM=Diabetes Mellitus, PCGM= personal real-time continuous glucose monitoring, RT-CGM=real-
time continuous glucose monitoring, CKD=chronic kidney disease, T1DM=Type 1 Diabetes Mellitus, T2DM=Type 2 Diabetes Mellitus, 
SMBG=self-monitoring blood glucose, RCT= Randomised Controlled Trial, SH=severe hypoglycaemia, HE=hypoglycemic event, 
DKA=diabetic ketoacidosis, CVD=cardiovascular disease, AV block=atrioventricular block, PPM=permanent pacemaker, iG=interstitial 
glucose, QOL=quality of life, GFI=Groeningen Frailty indicator, OR= Odds Ratio, 95%CI= 95% Confidence Interval, SU= sulfonylurea, 
DPP4 inhibitor=dipeptidyl peptidase-4 inhibitor, HbA1c=haemoglobin A1c, VT=ventricular tachycardia 
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